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Cannabis is the most commonly used illicit drug worldwide, with ~5 million daily users
worldwide. Emerging evidence supports a number of associations between cannabis
and psychosis/psychotic disorders, including schizophrenia. These associations-based on
case-studies, surveys, epidemiological studies, and experimental studies indicate that
cannabinoids can produce acute, transient effects; acute, persistent effects; and delayed,
persistent effects that recapitulate the psychopathology and psychophysiology seen in
schizophrenia. Acute exposure to both cannabis and synthetic cannabinoids (Spice/K2)
can produce a full range of transient psychotomimetic symptoms, cognitive deficits, and
psychophysiological abnormalities that bear a striking resemblance to symptoms of schizo-
phrenia. In individuals with an established psychotic disorder, cannabinoids can exacerbate
symptoms, trigger relapse, and have negative consequences on the course of the illness.
Several factors appear to moderate these associations, including family history, genetic
factors, history of childhood abuse, and the age at onset of cannabis use. Exposure to
cannabinoids in adolescence confers a higher risk for psychosis outcomes in later life and
the risk is dose-related. Individuals with polymorphisms of COMT and AKT1 genes may be
at increased risk for psychotic disorders in association with cannabinoids, as are individuals
with a family history of psychotic disorders or a history of childhood trauma. The relation-
ship between cannabis and schizophrenia fulfills many but not all of the standard criteria
for causality, including temporality, biological gradient, biological plausibility, experimental
evidence, consistency, and coherence. At the present time, the evidence indicates that
cannabis may be a component cause in the emergence of psychosis, and this warrants
serious consideration from the point of view of public health policy.
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INTRODUCTION
Psychotic disorders are arguably the most serious of mental ill-
nesses, the best known being schizophrenia. As yet, the etiology
of schizophrenia and other psychotic disorders remains unclear.
There is emerging evidence to support a number of associations
between cannabis and psychosis, but the precise nature of these
associations remains unclear.
Cannabis is the most commonly used illicit drug by adults, with
18.1 million current users in the U.S. in 2011 (up from 14.5 mil-
lion in 2007) and ~5 million daily cannabis users (1–3). In the
U.S., it was also the most commonly used illicit drug by children
12–17 years (7.9%) in 2011. The age at onset of regular cannabis
use appears to be occurring earlier. About 1.3% of eighth graders
endorsed daily use of cannabis in 2011 (3). Additionally, the aver-
age delta-9-tetrahydrocannabinol (THC) content of cannabis has
increased from 3.4% in 1993 to 8.8% in 2008, with concentrations
in high potency varieties such as sinsemilla increasing to as high
as 11.1% (4). “Medical” marijuana (cannabis) is being legalized
increasingly across the U.S. (5, 6). Some states have legalized recre-
ational cannabis use and others are projected to follow suit (7). As
a result, individuals, including those with a higher risk for psy-
chosis, who would not have risked the consequences of procuring
an illegal drug previously, may now consider exposing themselves
to cannabis.
In parallel, there is the emerging phenomenon of the recre-
ational use of Spice, a mixture of synthetic cannabinoids, by young
people (8). Among high school seniors, 11.4% reported using Spice
in the past year (9). In contrast to THC, the synthetic cannabi-
noids present in Spice are highly potent full cannabinoid 1 receptor
(CB1R) agonists (10, 11). There are a number of reports of acute
and persistent psychosis immediately following the use of Spice,
sometimes with catastrophic outcomes (12–14). In the U.S., emer-
gency department visits related to cannabinoids (149 ED visits per
100,000 population) were second only to cocaine (157.8 ED visits
per 100,000 population) (15).
Various lines of evidence point to associations between
cannabinoids and psychosis [reviewed in Ref. (16–18)]. These
associations may be categorized according to temporal proximity
of the onset of psychosis to exposure, duration, and clinical sig-
nificance of psychosis. Converging lines of evidence suggest that
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early and heavy exposure to cannabis is associated with a higher
risk for psychotic outcomes, including schizophrenia in later life
(18–28). In addition, cannabinoids can induce immediate-onset
psychotomimetic symptoms that do not persist beyond the period
of intoxication (~1 h), as reviewed by us (18). Finally, less well-
characterized but perhaps clinically important, cannabinoids are
also associated with acute episodes of psychosis that: (1) mani-
fest immediately following exposure, (2) last beyond the period of
intoxication, and (3) require clinical intervention (29, 30).
Furthermore, although the associations between cannabinoids
and psychosis have gained increasing recognition, the modera-
tors (i.e., variables that affect the direction and/or strength of
the relation between an independent, predictor variable – such
as cannabis use – and a dependent, outcome variable – such as
psychosis) and mediators (i.e., variables that directly account for
the relationship between cannabis use and psychosis) are less well-
understood. Emerging evidence suggests the crucial role of age of
exposure to cannabis (with the period of adolescence being iden-
tified as a period of exquisite vulnerability), familial risk, degree
of schizotypy, childhood trauma, and the role of genetic factors in
moderating this association.
As a preface to this review of the literature, several impor-
tant issues should be considered. Firstly, cannabis contains more
than 70 different cannabinoids (31) of which THC is thought to
be the main psychoactive ingredient, while another cannabinoid,
cannabidiol (CBD), is thought to have antipsychotic properties
(32). THC is hence not the same as cannabis, although most
of the experimental studies are conducted using THC. Secondly,
cannabis grown in different conditions and different parts of the
world has varying potencies based on the content of THC and
CBD. The type or potency of cannabis has rarely been accounted
for in epidemiological studies. Thirdly, it is important to make
a distinction between psychosis as a syndrome and psychosis-
like experiences (psychotomimetic effects). While psychosis refers
to a heterogeneous group of disorders defined as consisting
of positive symptoms (delusions, hallucinations, and thought-
alienation phenomena), negative symptoms (alogia, avolition,
anhedonia, asociality, and affective flattening), and disorganiza-
tion/cognitive symptoms (deficits in attention, working memory,
problem-solving, and executive function); psychosis-like experi-
ences are characterized by a loss of reality-testing and include
derealization, depersonalization, dissociation, hallucination, para-
noia, impairment in concentration, and perceptual alterations,
which are transient and self-limited. The fact that schizophre-
nia is a syndrome that is much more than positive symptoms
needs to be considered. Negative (e.g., amotivation, asociality, and
anhedonia) and cognitive symptoms (e.g., deficits in attention,
memory, and executive function) contribute to the disease burden
of schizophrenia just as positive symptoms do.
Below herewith, we review existing literature on the association
between cannabinoids and psychosis with special focus on the
recent critical literature. We categorized major findings into the
following categories: immediate psychotic symptoms, psychosis
outlasting intoxication, delayed and persistent effects, modera-
tors, and mediators of the association (age of exposure, family
history, history of childhood abuse, and genetics), and evidence
for causality.
IMMEDIATE AND SHORT-LIVED EFFECTS OF CANNABINOIDS
NON-EXPERIMENTAL EVIDENCE
Evidence from anecdotal reports and surveys of the effects of
cannabis
The evidence from anecdotal reports suggests that cannabis may
induce acute psychotomimetic effects and precipitate the syn-
drome of psychosis. One of the earliest systematic studies of the
psychotomimetic effects of cannabis was that by the French psychi-
atrist Jacques-Joseph Moreau (de Tours) in his 1845 book, Hashish
and Mental Illness (33). He reported that hashish (cannabis
resin) could precipitate “acute psychotic reactions, generally lasting
but a few hours, but occasionally as long as a week; the reac-
tion seemed dose-related and its main features included paranoid
ideation, illusions, hallucinations, delusions, depersonalization, con-
fusion, restlessness, and excitement. There can be delirium, disorien-
tation, and marked clouding of consciousness” (33). Numerous case
reports have since then documented the acute psychotomimetic
symptoms of cannabis intoxication, including depersonaliza-
tion, derealization, paranoia, ideas of reference, flight of ideas,
pressured thought, disorganized thinking, persecutory delusions,
grandiose delusions, auditory/visual hallucinations, and impair-
ments in attention and memory (30, 33–42) in about 20–50% of
individuals (43, 44).
In a survey of ultra-high-risk and recent-onset patients with
psychosis (45), 37% of subjects reported that their first psychotic
symptoms appeared during cannabis intoxication. The subjects
also reported feeling more anxiety, depression, and suspicious-
ness immediately after cannabis use than cannabis-using controls.
Another recent study of first-episode psychosis (FEP) patients
(n= 109) found that daily cannabis users were significantly more
likely to have an acute onset of psychosis than non-daily users
(46). Evidence from case reports and surveys is limited, however,
by confounds such as observer bias, effects of other illicit drugs,
and failure to exclude negative and cognitive symptoms prior to
onset of positive symptoms.
Evidence from anecdotal reports and surveys of the effects of
medicinal cannabinoids
With the pioneering work of Mechoulam in 1964, the individual
constituents of cannabis were characterized (47). The identifica-
tion of THC as the main psychoactive agent led to the synthesis
of dronabinol (synthetic THC) and other non-psychotropic syn-
thetic cannabinoids such as levonantradol and nabilone (9-trans-
ketocannabinoid), which were thought to have specific antiemetic,
analgesic, and antispastic effects. The use of these agents for the
treatment of pain syndromes, chemotherapy-induced nausea, and
spasticity in multiple sclerosis was followed by reports of transient
psychotomimetic effects among patients. The psychotomimetic
effects reported were similar to that with cannabis including “loss
of control,” thought disturbances, feelings of unreality, apprehen-
sion, fear and paranoia, anxiety and panic, dissociation, deper-
sonalization, dysphoria, difficulty concentrating, hallucinations,
perceptual alterations, amnesia, and anxiety (48–62). These effects
were dose-related and proportional to the affinity of the com-
pound for the CB1R. The high incidence of intolerable behavioral
side effects in fact, led to the discontinuation of drug develop-
ment of levonantradol as an analgesic. In a systematic review of
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30 studies that examined the efficacy of dranabinol, nabilone,
or levonantradol for chemotherapy-induced nausea and vomit-
ing Machado Rocha et al. (63) found that synthetic cannabinoids
was responsible for 30% of dropouts; with 6% patients devel-
oping hallucinations and 5% developing paranoia. In another
systematic review, Tramer et al. (64) found that patients receiv-
ing synthetic cannabinoids had a higher relative risk of developing
dysphoria or depression [RR 8.06 (95% CI 3.38–19.2)], hallucina-
tions [RR 6.10 (95% CI 2.41–15.4)], and paranoia [RR 8.58 (95%
CI 6.38–11.5)] than those receiving non-cannabinoid antiemet-
ics. Importantly, hallucinations and paranoia were seen exclusively
with cannabinoids, and not with other antiemetic agents; and these
effects appeared to be related to dose, potency, and frequency of
administration.
Evidence from anecdotal reports and surveys of the effects of
synthetic cannabinoids (Spice, K2)
The emergence of potent synthetic cannabinoids as drugs of abuse
in the last decade provide another source of evidence point-
ing to the link between cannabinoids and psychosis (8). These
compounds, collectively referred to as Spice or K2, comprise a mix-
ture of synthetic cannabinoids such as CP-47,497, CP-47,497-C8,
JWH-018, JWH-073, JWH-081, JWH-122, JWH-210, JWH-250,
HU-211, and RCS-4 (65–72). It should be noted that, unlike
THC, which is a weak partial agonist of brain CB1Rs, the syn-
thetic cannabinoids are highly potent, full agonists of CB1R, which
would predict more robust effects. Spice has gained popularity as a
drug of abuse since it is more psychoactive than cannabis, is readily
available over the Internet (advertised as“natural herbs”or“harm-
less incense” under brand names such as Spice, K2, Yucatan Fire,
Skunk, Moon Rocks), and is non-detectable in standard urine tox-
icological tests. In some countries, including much of the United
States and Canada, synthetic cannabinoids are available at gas sta-
tions and head-shops as natural herbs and incense; this contributes
to its perception as safe and legal among users.
There are no controlled-studies on the psychotomimetic effects
of synthetic cannabinoids (73); available information about their
effects in humans consists of retrospective case reports from emer-
gency room (ER) visits (69, 70, 74), surveys (12–14), reports from
the American Association of Poison Control Centers (AAPCC)
(75), and from media and law-enforcement agencies on cat-
astrophic events related to their use (76–81). There has been
a substantial increase in ER visits resulting from acute behav-
ioral effects following use of these synthetic cannabinoids. The
psychotomimetic effects reported include anxiety, agitation, dis-
orientation, hallucinations, and paranoia (69, 70, 82–84). In an
Internet survey, Spice/K2 users most commonly endorsed feeling
paranoid (11%), hallucinating (3%), and feeling as if in a dream-
like state (26%)“most of the time”or“every time”they used“Spice”
(14). The AAPCC reported an exponential increase in call volume
related to the use of Spice/K2 from 53 calls in 2009 to over 6000
in 2011 with callers reporting symptoms of agitation, drowsiness,
and hallucinations (62% of calls) (75).
Case reports document the ability of these compounds to pre-
cipitate a psychotic relapse in patients with pre-existing psychotic
disorders and psychotic symptoms in those with no prior history of
psychosis (12, 74, 85). Müller et al. (86) reported on a 25-year-old
man with a history of psychotic episodes precipitated by cannabis
use and a family history of schizophrenia who had been stable
for 2 years and had a psychotic relapse comprising anxiety, para-
noid delusions, and hallucinations after smoking Spice on three
occasions in 1 month. Every-Palmer described sudden agitation,
disorganization, and delusions in five forensic patient who had
consumed Spice containing JWH-018 and/or CP-47,497 (85). Of
the five patients, only one retained insight into the possible psy-
chotogenic nature of “Spice” (85). In a follow up survey of 15
inpatients with serious mental illness in a forensic psychiatric facil-
ity, Every-Palmer reported that patients commonly experienced
anxiety and psychotomimetic effects, few developed tolerance, and
none reported withdrawal symptoms (12).
Psychotic symptoms are also reported in patients with no pre-
vious history of psychosis. The adverse clinical events documented
in case reports include altered consciousness, confusion, anxi-
ety, irritability, agitation, paranoia, hallucinations, and psychosis
(70, 82, 85–87). However, the majority of case reports to date
discuss people 25 years or younger (84, 88). Therefore, it is pos-
sible that “Spice” exacerbates a pre-existing prodromal syndrome.
Case reports and cross-sectional surveys are only able to show an
association and cannot elucidate causation.
The sparse literature on Spice/K2 effects reviewed above has
a number of limitations, including selection bias, reliance on the
accuracy of written record or subject recall, uncontrolled nature
of the evidence, the inadequate characterization of cases, lack
of standardized assessments, confounding effects of concomitant
drug use, different doses and routes of administration, and vari-
able individual expectancy, set, and setting. Cases reported by the
media and law-enforcement may represent extremes that might
not be generalizable. The temporal profile, range, and intensity
of Spice/K2 effects, and whether the effects are dose-related or
biphasic, are not known. Furthermore, the relationship between
dose, effects, and blood/urine levels of the parent compound and
metabolites is not known.
IMMEDIATE EFFECTS OF CANNABINOIDS: EXPERIMENTAL
EVIDENCE
Experimental studies provide an opportunity to control variables
such as dose, route of administration, and setting, while employing
a randomized-control paradigm. Studies have variously examined
the effects of smoked cannabis, cannabis extract, oral, and intra-
venous THC and CBD on positive psychotomimetic symptoms,
negative symptoms, cognitive, and psychophysiological measures.
Although, early semi-experimental studies of cannabis in the
early 1900s using oral cannabis or cannabis extract [reviewed
in Ref. (18)] demonstrated cognitive and perceptual effects of
cannabis, D’Souza et al. (89) were the first to characterize the
profile of positive psychotomimetic symptoms, negative symp-
toms, and cognitive effects of intravenous THC in healthy indi-
viduals. Despite varying routes of administration, experimental
studies have yielded some consistent results regarding the effects
of cannabis, THC, and CBD. There have, however, not been any
controlled experimental studies of the synthetic cannabinoids in
humans to date.
In the following sections, we provide a brief summary of
the consistent effects noted with cannabis, THC, and CBD.
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Interestingly, cannabis and THC produce the full range of positive
psychotomimetic symptoms, negative symptoms, and cognitive
deficits seen in schizophrenia, while CBD has been shown to have
anxiolytic properties and even inhibit the psychotomimetic effects
of THC (90–92).
POSITIVE SYMPTOMS
Cannabis extract containing predetermined quantities of THC
(93, 94) and THC alone (32, 73, 89, 92, 94–99) have been shown
to produce a range of transient, positive symptoms, that are
qualitatively similar to the positive symptoms of schizophrenia.
These symptoms include suspiciousness, paranoid and grandiose
delusions, conceptual disorganization, fragmented thinking, and
perceptual alterations. Additionally, cannabis and THC also result
in depersonalization, derealization, alterations in sensory percep-
tion, and feelings of unreality. These effects have consistently been
demonstrated with smoked cannabis, oral cannabis extract/THC
(dose range 5–20 mg), intravenous THC (dose range 0.015–
0.03 mg/kg), and intrapulmonary administration via a vaporizer
(32, 73, 89, 92, 94–99). In the first study of its kind in a carefully
controlled laboratory setting, D’Souza et al. (89), administered
intravenous THC in two doses (2.5 and 5 mg), in a double-blind,
randomized, placebo-controlled study in healthy adults (n= 22).
Subjects were screened to rule out significant psychiatric disorder
or family history of Axis I disorders (89). The study found that
THC produced transient positive psychotic symptoms (Figure 1)
including perceptual alterations, negative symptoms, mood symp-
toms such as euphoria and anxiety,and also cognitive deficits, espe-
cially in attention, working memory, and verbal recall (Figure 2).
In a similar study in healthy individuals, using almost identical
methods except for a lower dose of THC, Morrison et al. (95)
showed that intravenous THC (2.5 mg) produced similar effects
on positive psychotic symptoms, mood, and cognition.
The effects of dopamine D2-receptor antagonists on the psy-
chotomimetic effects of THC are not clear. For example, in some
studies, olanzapine (101) and haloperidol (102) were shown to
attenuate the psychotomimetic effects of THC. However, D’Souza
et al. showed that acute treatment with haloperidol did not atten-
uate the psychotomimetic effects of THC in healthy subjects (103)
and chronic antipsychotic treatment failed to protect schizophre-
nia patients from the symptom exacerbating effects of THC (104).
The potential antipsychotic and anxiolytic effects of CBD have
drawn increasing attention. In a functional magnetic resonance
(fMRI) study of brain responses to emotional expression of faces,
Fusar-Poli et al. (90) found that while THC resulted in increased
psychotic symptoms and increased skin conductance responses
during processing of fearful faces; CBD, on the other hand led to a
reduction in anxiety and a decrease in skin conductance response.
A separate fMRI study showed that THC and CBD had oppo-
site effects on blood oxygen-level dependent (BOLD) responses in
tasks of verbal recall, response-inhibition, processing fearful facial
expressions, auditory processing, and visual processing (91). Some
limitations notwithstanding, this study provided some important
leads into the differential effects of CBD and THC.
Time perception abnormalities are known to occur in
schizophrenia, but have received little attention (105–108).
Cannabinoids have been shown to alter time perception in both
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FIGURE 1 | Effects ofTHC on the seven-item positive symptom and
negative symptoms subscales of the Positive and Negative Syndrome
Scale (PANSS). THC at both a low dose (2.5 mg) (green) and moderate
dose (5 mg) (100) induce an increase in positive and negative symptoms,
compared to placebo (yellow). Adapted from Ref. (89).
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FIGURE 2 | Effects ofTHC on the clinician- and subject-rated subscales
of the Clinician Administered Dissociative Symptoms Scale (CADSS), a
measure of perceptual alterations. THC at both a low dose (2.5 mg)
(green) and moderate dose (5 mg) (100) induce an increase in perceptual
alterations as rated by the clinician and the subject, compared to placebo
(yellow). Adapted from Ref. (89).
preclinical (109–112) and clinical studies (113–117). In the largest
double-blind, randomized, cross-over, placebo-controlled study
to date, Sewell et al., showed that THC at different doses induced
time overestimation and underproduction compared with placebo
(118). Cannabinoids have also been found to disrupt perfor-
mance on visual information processing in the binocular depth
inversion task, a potential surrogate marker for psychosis seen
in patients with acute paranoid schizophrenic or schizophreni-
form psychosis (119). This effect has been observed with cannabis
resin (120), nabilone (a synthetic analog of THC) (121), dronabi-
nol (a synthetic isomer of THC) (119), and in chronic cannabis
users (122).
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NEGATIVE SYMPTOMS
Delta-9-tetrahydrocannabinol also produces a range of effects sim-
ilar to the negative symptoms of schizophrenia, including blunted
affect, emotional withdrawal, psychomotor retardation, lack of
spontaneity, and reduced rapport (89, 97). It is difficult to deter-
mine whether these “negative symptoms” were primary or were a
consequence of the sedating and cataleptic effects of cannabinoids
observed in animal studies. Morrison et al. (97) however, showed
that the effect of THC on negative symptoms was independent of
effects on sedation. It is also unclear if the negative symptoms were
a manifestation of internal preoccupation with positive psychotic
experiences. Furthermore, acute pharmacological studies may be
limited in their capacity to model negative symptoms.
COGNITIVE DEFICITS
Cannabis, THC and other synthetic cannabinoids also produce
transient, dose-related cognitive impairments, especially in the
domains of verbal learning, short-term memory, working mem-
ory, executive function, abstract ability, decision-making, and
attention (123–129). These effects are not limited to humans but
are also seen in rodents and non-human primates [reviewed in
Ref. (130, 131)]. Interestingly, the profile of impairment observed
in different cognitive domains is similar to that observed in
schizophrenia (132).
The cognitive impairment produced by THC is most pro-
nounced in the domain of verbal learning and memory (129),
which is also one of the domains of significant impairment in
schizophrenia (132). Figure 3 illustrates the effects of THC on the
Hopkins Verbal Learning Test (HVLT) in healthy subjects (104).
THC has been shown to produce robust dose-dependent impair-
ments on both immediate and delayed (30 mins) verbal recall.
THC also increased the number of “false positives” and “intru-
sions” on the HVLT. Similar findings have been recently reported
by Henquet et al. (133) and Morrison et al. (95).
The acute effects of cannabinoids are likely modulated by
genetic and personality factors. This would explain why only a
small minority of people experience the psychotomimetic effects
of cannabinoids. Henquet and colleagues examined the effects of
the interaction of Catechol-O-methyl transferase (COMT) poly-
morphism and a trait index of psychosis liability on smoked THC
(0.3 mg/kg) on cognitive performance and psychosis in 30 healthy
individuals (133). They found that individuals with the Val/Val
polymorphism and high scores on psychosis liability had higher
THC-induced psychotic symptoms.
PSYCHOPHYSIOLOGICAL EFFECTS
Psychophysiological effects refer to measures that attempt to exam-
ine the physiological basis of psychological processes. In the study
of cannabinoids, these effects have primarily been demonstrated
using electroencephalography (EEG). EEG measures of infor-
mation processing, such as event-related potentials (ERPs) and
neural oscillations, offer a more proximal index of neural events
in humans with exquisite temporal precision (134). ERPs are aver-
aged EEG responses time-locked to particular stimuli or events.
ERPs relevant to psychosis include: (1) P50 – a measure of audi-
tory sensory gating, (2) P300b – a measure of directed attention,
contextual updating of working memory, and the attribution of
Δ-9-THC impairs verbal memory
(Hopkins Verbal Learning Test) 
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FIGURE 3 | Effects ofTHC on the immediate free recall, delayed free
recall, delayed cued, and recognition recall measured by a 12-word
learning task (HopkinsVerbal LearningTest), a measure of verbal
memory. THC at both a low dose (2.5 mg) (blue) and moderate dose (5 mg)
(100) induce an immediate free recall, delayed free recall, delayed cued, and
recognition in patients with schizophrenia (solid line) and healthy individuals
(dotted line), compared to placebo (yellow). Adapted from Ref. (89).
salience to deviant or novel stimuli (135), (3) P300a – a measure
of novelty detection, and (4) mismatch negativity (MMN) – a
measure of processing and memory of deviant stimuli. These ERP
measures have been reported to be abnormal in schizophrenia and
have been considered biomarkers of the disorder. Abnormalities
in neural oscillations have also been noted in schizophrenia and
in chronic cannabis users.
Deficits in auditory sensory gating, as demonstrated by a dis-
ruption in P50 response, have been shown in patients with schizo-
phrenia (136–140). The cannabinoid agonists CP-55940 and WIN
55,212-2 have been shown to disrupt sensory gating in rats (141,
142). However, there are no studies that have examined the acute
effects of cannabinoids on sensory gating (P50) in humans. In con-
trast, there are cross-sectional studies comparing heavy, chronic
cannabis users to healthy controls that have shown that chronic
cannabis users show disruptions in P50 suppression (143, 144),
which was evident despite subjects abstaining for 24 h. These
findings suggest that chronic cannabis use is associated with dis-
ruption in sensory gating. Furthermore, the degree of disruption
in sensory gating was found to correlate positively with the magni-
tude of cannabis exposure (138, 145), suggesting a dose-response
relationship.
The P300 is a late positive, post-attentional ERP component
thought to be related to directed attention, contextual updating
of working memory, and the attribution of salience to deviant or
novel stimuli (135). Deficits in P300 amplitude and latency have
been demonstrated in patients with schizophrenia (136, 139, 146–
152). THC has been shown to cause a reduction in the amplitude
of the P300 response in several paradigms such as a visuospatial
N-back working memory task (153), and auditory choice reaction
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task (154, 155). D’Souza et al. examined the effect of several doses
of intravenous THC on the P300 response in healthy individuals
and showed that THC decreased the amplitude of both the novelty
P300a and target P300b (155), while also producing concomitant
psychotomimetic effects. There was no impairment in the latency
of the P300 response or in the N100 response, indicating that
THC disrupted cortical processes responsible for context updating
(P300b) and the automatic orientation of attention (P300a), with-
out affecting early sensory registration (N100) or processing speed.
Studies of chronic cannabis users have however been equivocal,
with studies variably showing decreased P300 amplitudes (156),
increased P300 latency (157), increased P300 amplitude (157, 158),
or shorter P300 latency (159). Although the reasons behind these
discrepant results are unclear, it is possible that chronic cannabis
users are impaired during more cognitively challenging selective
attention tasks (156, 157, 160), but retain normal ERP responses
during simple dual-stimulus discrimination tasks (158, 159).
Mismatch negativity is an automatic, pre-attentive, and
negative-voltage ERP component that occurs ~100–200 ms after
a deviant auditory stimulus that differs in frequency or duration
from a sequence of standard auditory stimuli. It is thought to rep-
resent basic auditory information processing, and sensory mem-
ory generated primarily in the superior temporal and prefrontal
cortex (PFC), while being relatively independent of attention (161,
162). Deficits in MMN have been shown in patients with schizo-
phrenia, early psychosis, and high-risk subjects (163, 164). While
oral THC did not produce any acute changes in MMN ampli-
tude (93), studies in chronic cannabis users have demonstrated
decreased MMN amplitudes in the frequency deviance condition
(154, 165–167). There also appears to be a dose–response effect in
the MMN response with long-term and heavier users of cannabis
demonstrating significantly lower MMN amplitudes compared
to short-term or light users and duration of cannabis exposure
showing a negative correlation with MMN amplitudes (154, 165).
Cannabinoids have been shown to disrupt theta band (4–8 Hz)
neural oscillations in rats (168). Similar disruption in theta band
power was demonstrated following smoked cannabis (169). The
degree of disruption in theta band power correlated with deficits
in working memory performance in this study. Studies of neural
oscillations in chronic cannabis users have demonstrated attenua-
tion of high frequency activity in the beta range (13–29 Hz) (145,
170) and in the gamma range (30–50 Hz) (145, 171). These find-
ings are very interesting in light of accumulating evidence that
schizophrenia may be primarily a disorder of abnormal neural
oscillations and synchrony [reviewed in Ref. (172)] and that neural
oscillations may also be important in the organization of the
networks in the brain (173).
ACUTE PSYCHOSIS OUTLASTING INTOXICATION
The use of cannabinoids are also associated with acute episodes
of psychosis that: (1) manifest immediately following exposure,
(2) last beyond the period of intoxication, and (3) sometimes
require clinical intervention. This is distinct from the effects pre-
viously described, which do not outlast the period of intoxication.
Most of the literature about this phenomenon comes from small
case series and case reports. The phenomenology, duration, and
course of such cases – which we refer to as cannabis-induced acute
and persistent psychosis (CIAPP) – have not been systematically
characterized.
In the 1890s, the Indian Hemp Drugs Commission undertook
a study to examine the effects of cannabis use. The commission
reported that “excessive” cannabis use was responsible for psy-
chotic reactions in 9.5% (222/2344) of cases in asylums in India.
Chopra et al. reported a series of patients admitted to a psy-
chiatric hospital in India for cannabis related psychosis (29, 30).
The psychosis was typically preceded by ingestion of large doses
of cannabis and was characterized by hallucinations, delusions,
paranoia, depersonalization, amnesia, emotional lability, confu-
sion, and disorientation. Similar case series have been reported
from other geographical areas including Sweden, Denmark, the
Caribbean, Scotland, UK, USA, and South Africa (37, 174–181).
These case reports suggest that when cannabis use is stopped,
the acute psychotic episodes resolve (quicker in comparison with
“endogenous” psychoses) (37, 39, 177, 178, 180, 182–186), and do
not recur unless cannabis use resumes [reviewed in Ref. (187)].
However, since follow up was only for a few months, the long-
term course and outcome, the clinical implications, and prognostic
significance of these cases remains unclear. Several recent large
(n=~20,000) studies suggest that,over long-term (~8 year) follow
up, ~50% of patients without any pre-existing psychiatric disorder
who were hospitalized for cannabis-induced psychosis, were later
re-diagnosed with a schizophrenia-spectrum disorder (181, 188);
that number increased to ~75% when the diagnosis included any
psychotic outcome (181). These observations suggest that hospi-
talization for CIAPP may be a harbinger of a recurrent psychotic
disorder that we currently classify as schizophrenia. More recent
case reports and retrospective studies continue to demonstrate
the close temporal relationship between use of cannabis and the
onset of a psychotic disorder, sometimes quite indistinguishable
from schizophrenia (189, 190). In fact, the International Classi-
fication of Diseases-10 (ICD-10) allows for the psychotic effects
of cannabis to be coded as both an acute polymorphic psychotic
disorder and a protracted substance-induced psychotic disorder.
It is conceivable that, as suggested by Rounsaville (191), these cases
may actually represent a distinct persistent psychotic disorder.
DELAYED AND PERSISTENT EFFECTS OF CANNABINOIDS
The evidence for persistent effects of cannabinoids in humans
comes from large-scale epidemiological studies and from studies
in chronic cannabis users. In the following section, we examine the
evidence linking cannabis use and persistent psychotic disorder,
including negative and cognitive symptoms.
PERSISTENT PSYCHOTIC DISORDER
The evidence for the association between cannabis use and persis-
tent psychosis comes from both cross-sectional studies (192–196)
and longitudinal epidemiological studies, including the Swedish
military conscript cohort (197–199), the Netherlands Mental
Health Survey and Incidence Study (NEMESIS) (20), the German
prospective Early Developmental Stages of Psychopathology Study
(EDSP) (24), the Dunedin cohort (19, 200), and the Christchurch
Health and Development Study (CHDS) birth cohort (23).
The first study to draw attention to the association between
cannabis use and psychosis was the Swedish conscript study (197),
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in which Andreasson et al. followed a cohort of 45,570 Swedish
military conscripts (97% of all Swedish males aged 18–20 years)
from 1969 to 1970. The investigators observed a dose–response
relationship between cannabis use (via self report) at initiation of
military service and hospitalization for a psychotic disorder over
the ensuing 15 years, with maximal risk among those who had
smoked cannabis more than 50 times. Conscripts who reported
having used cannabis at least once in their lifetime had a 2.4-fold
(95% confidence interval 1.8–3.3) increased risk of developing
schizophrenia over the course of 15 years. This relative risk rose
to sixfold (95% CI 4–8.9) in those who had used cannabis more
than 50 times in their lifetime. The risk remained significantly high
despite adjusting for other factors such as psychiatric illness at the
time of conscription, solvent abuse, and parental separation. In a
27-year follow up study of the same cohort and a re-analysis of
the data, Zammit et al. replicated the findings of Andreasson et al.,
showing that cannabis use was associated with a linear increase
in the risk of developing schizophrenia; the relative risk increas-
ing from 2.2 (95% CI 1.7–2.8) in those who had used cannabis
at least once, to 6.7 (95% CI 4.5–10) in those who had used
cannabis more than 50 times in their lifetime (198). When poten-
tial confounders such as IQ sore, disturbed behavior in childhood,
psychiatric diagnosis at conscription, cigarette smoking, degree
of social integration, and place of upbringing were included in
the regression analysis, the adjusted relative risk was 1.5 (95% CI
1.1–2.0) in those who had used cannabis at least once and 3.1
(95% CI 1.7–5.5) in those who had used cannabis more than 50
times in their lifetime. The relative risk for schizophrenia was sig-
nificantly higher in those who developed schizophrenia within
5 years of conscription, which raises questions about the direction
of causality. In other words, this preliminary analysis could not
distinguish whether cannabis use led to schizophrenia or whether
subjects used cannabis in an attempt to self-medicate incipient
symptoms of schizophrenia. In a secondary analysis that excluded
those who developed a diagnosis of schizophrenia within 5 years of
conscription, the adjusted relative risk remained significant only
for those who had used cannabis more than 50 times (adjusted
relative risk= 2.5, 95% CI 1.2–5.1). The study needs to be inter-
preted with caution: while 24.3% of the sample had used any
drug, a very small percent (3.4%) had used only cannabis. While
the analysis controlled for cigarette smoking, it failed to control
for the use of stimulants and other drugs. Also, the fact that pre-
sumably weak confounders (such as “place of upbringing” and
“cigarette smoking”) contributed substantially, along with other
variables in reducing the adjusted relative risk by ~50% in the
regression analysis highlights the difficulties inherent in interpret-
ing epidemiological data and raises the issue of other unknown
confounders. Similar criticisms of the studies from the Swedish
conscript cohort have been raised by other authors (201–203),
including the facts that: (a) the use of other drugs was more com-
mon in the cannabis-using group, (b) the association between
cannabis use and schizophrenia may be mediated by a third, as
yet unknown factor, and (c) the follow up study, a quarter century
later, failed to address the issue of confounding due to use of other
drugs, many of which are also known to precipitate psychosis.
Using the NEMESIS cohort, van Os et al. reported that cannabis
use at baseline was associated with an increased risk of psychosis
(20). The study assessed 7076 subjects at baseline (1996), 5618
subjects at a first time-point (1997), and 4848 subjects at a second
time-point (1999) via telephonic interviews, and found 10 subjects
who developed psychosis, while 38 subjects endorsed individual
items on the Brief Psychiatric Rating Scale (BPRS). The findings
of the study are limited by the small numbers in the outcome of
interest (25) despite the large sample size.
The EDSP study, which used in-person interviews in the
assessment of 923 individuals from the general population (aged
14–24 years), showed that cannabis use was associated with an
increased risk of psychotic symptoms and persistent use increased
this risk further (28). Importantly, this study yields evidence for
a unidirectional relationship between cannabis use and psychosis.
This is in contrast with another recent study (22), which showed
the relationship to be bi-directional, alluding to the possibility of a
phenomenon of “self-medication,” a topic that is further discussed
below.
The Dunedin cohort study (19) examined data from 759 sub-
jects of the population birth cohort comprising 1037 individuals
born in Dunedin, New Zealand, in 1972–1973. The study col-
lected information on psychotic symptoms at age 11, drug use at
ages 15 and 18 years, and assessed psychiatric symptoms at age 26.
Cannabis use by age 15 and 18 years was found to be associated
with more schizophrenia symptoms at age 26 years; and the asso-
ciation remained significant despite controlling for the presence
of psychotic symptoms at age 11 years. The association was also
found to be stronger with earlier use. Those who used cannabis by
age 15 years were also four times more likely to have a diagnosis of
schizophreniform disorder; the risk was reduced by 31% and no
longer significant after controlling for psychotic symptoms at age
11 years, pointing to the possibility of reverse-causality.
Fergusson et al. attempted to validate a possible causal link
between cannabis use and psychosis in a dataset of a 25-year longi-
tudinal study in New Zealand (the CHDS birth cohort comprising
1265 children) (23). The study showed that daily use of cannabis
was associated with 2.3- to 3.3-fold higher risk of psychosis than
among non-users. One of the limitations of the study is that the
data was derived from 10 items of the Symptom Checklist-90, the
items on which overlap with personality traits such as schizotypy
and paranoia and that the study did not attempt to delineate psy-
chotic symptoms due to the acute effects of cannabis use from
persistent effects (204).
This finding of increased psychosis risk has been reported in
several other prospective studies (19–21, 24). The cumulative evi-
dence for the association between cannabis and psychosis have
been examined in five systematic reviews (25, 205–208), four of
which (25, 205, 207, 208) found a consistent association between
cannabis use and psychosis. The review by Macleod et al. (206) did
not find a consistent association, but has been critiqued for failure
to perform a meta-analysis. The inconsistent results of the sys-
tematic reviews are also likely due to different inclusion/exclusion
criteria, different methodology, and different outcome measures
(209). In the latest systematic review by Moore et al., any cannabis
use (pooled adjusted OR= 1.41, 95% CI 1.20–1.65) was asso-
ciated with a 40% increased risk of psychotic disorder, and the
risk increased in a dose-dependent fashion with greater cannabis
exposure (OR= 2.09, 95% CI 1.54–2.84) (25).
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While the evidence supporting an association between cannabis
exposure in adolescence and later psychosis is largely consistent,
the evidence has been challenged on many counts (210), including
sampling bias; under-powered sample sizes; presence of unknown
confounders; difficulty distinguishing psychotic symptoms from
psychotic disorder in longitudinal studies; direction of causal-
ity; lifetime exposure to multiple drugs; and period-, time-, and
cohort-effects.
NEGATIVE SYMPTOMS
Chronic and heavy cannabis use has been associated with a
syndrome characterized by a predominance of negative symp-
toms, referred to as an “amotivational syndrome” (175, 187,
211–213). The features of this syndrome include apathy, amoti-
vation, social withdrawal, narrowing of one’s personal repertoire
of interests, lethargy, impairment in memory and concentra-
tion, impaired judgment and decision-making, and poor socio-
occupational functioning. All these symptoms share similarities
with the negative symptoms of schizophrenia. The nosological sta-
tus of the syndrome is, however, debated. Further, the confounding
effects of concomitant poly-substance abuse, poverty, low socio-
economic status, or pre-existing psychiatric disorders may explain
the association (214, 215).
This literature is in contrast with the finding that healthy,
cannabis users have lower scores on negative schizotypy com-
pared to healthy, drug-free individuals (158, 216), and that patients
with schizophrenia who use cannabis have less negative symptoms
compared to those who do not use cannabis (217, 218). The cross-
sectional nature of these studies and lack of information regarding
scores at baseline makes it difficult to conclude if cannabis does
not indeed cause a worsening of negative symptoms compared to
baseline.
COGNITIVE DEFICITS
Several studies suggest that chronic, heavy cannabis use leads to
impairments in memory, attention, working memory, executive
function and IQ (219–227). Solowij and Mitchie suggested that
cognitive dysfunction associated with long-term or heavy cannabis
use is a cognitive endophenotype of schizophrenia (139). In a com-
prehensive review, Solowij and Battisti concluded that chronic
heavy cannabis use was associated with impairments in mem-
ory (224) that persisted beyond the period of acute intoxication
and was related to the frequency, duration, dose, and age of onset
of cannabis use. Fontes et al. evaluated the neuropsychological
performance of 104 chronic, heavy cannabis users and found
that, compared to controls, chronic cannabis users had signifi-
cant impairment on the cognitive domains of sustained attention,
impulse control, and executive functioning (226). Additionally,
similar to the literature on the risk of psychosis, individuals who
used cannabis in adolescence (before the age of 15 years) had
greater deficits. The authors however, did not assess whether sub-
jects were in withdrawal or had residual effects from their last use
of cannabis at the time of assessment.
While chronic, heavy cannabis users have deficits in cogni-
tive processes, especially memory and attention in the context
of ongoing cannabis use, the question of whether these impair-
ments are persistent or a result of withdrawal and residual effects
is unclear. While one study demonstrated an absence of persis-
tent neuropsychological deficits in frequent long-term cannabis
users after 28 days of abstinence (228), other studies have shown
variable durations to full recovery, ranging from a week (229),
to 28 days (221), to 3 months of abstinence (230), with some
studies showing recovery only after an average of 2 years of absti-
nence (187, 231). A recent review provides a summary of the
literature to date (225). Among studies in which neuropsycho-
logical assessments were performed 3 weeks or later after last use
of cannabis, five out of seven studies showed no impairment in
attention (221, 228, 232–236), while two showed persisting impair-
ment (222, 231). One study revealed a trend toward impairment
in decision-making/risk-taking (237). There was no impairment
on response-inhibition measured by the Stroop test (221, 222,
233–235), and on working memory (236) while all (221, 222, 233,
234) but one (235) found an impairment on the Wisconsin Card
Sorting Test, a test of set shifting. There was no impairment in
verbal memory in two (228, 233) of the three studies that used the
Buschke’s Selective Reminding Test (BSRT), a test of memory of
word lists. When the data from the third study (234) was stratified
based on age at onset of cannabis use, significantly greater impair-
ment was noticed in those who had first use cannabis before the age
of 17 years, suggesting that, as for positive symptoms, earlier age
of onset of cannabis use may be associated with greater persistent
cognitive deficits. It is important to note that none of these studies
were designed to determine whether the cognitive impairments
predated cannabis use.
Previous cross-sectional experiments have reported inconsis-
tent results with some suggesting that chronic cannabis use impairs
performance on tests of intelligence (238, 239), while others
finding no impairment (240, 241). A recent longitudinal study
examined 1037 subjects followed from birth to age 38 years (242).
Cannabis use was evaluated at ages 18, 21, 26, 32, and 38 years
while neuropsychological testing was conducted at ages 13 and
38 years. The experiment determined that those who persistently
use cannabis are more likely than non-users to experience a signifi-
cant decline in IQ. The findings persisted even after controlling for
level of education and impaired IQ was found to be particularly
true for the subjects who began to use cannabis during adoles-
cence as opposed to during adulthood. Those who began to use
cannabis during adolescence exhibited an eight-point decrease in
IQ between childhood and adulthood. Another important finding
of the study was that the decline in IQ did not appear to reverse
after cannabis use ceased (242).
Some studies that have examined cognitive performance among
patients with schizophrenia have made a case that patients with
schizophrenia and comorbid cannabis abuse have better cogni-
tive performance than patients without comorbid cannabis abuse
(243–246). Emerging evidence, however, suggests that patients
with cannabis use have higher premorbid IQ (247). The findings
are not inconsistent with the experimental data; it is likely that
persons who smoke cannabis have higher premorbid IQ, as evi-
denced by their ability to procure an illegal substance while evading
the law. Therefore, although continued cannabis use results in a
decline in their individual cognitive performance (242, 248, 249),
when compared to non-users they appear to have relatively better
cognitive performance. Furthermore, abstinence from cannabis
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may be associated with better cognitive performance among male
patients with schizophrenia (248).
MODERATORS/MEDIATORS OF THE LINK BETWEEN
CANNABIS AND PSYCHOSIS
AGE OF EXPOSURE
Epidemiological evidence suggest that the earlier the age of expo-
sure to cannabis, the greater the risk of a psychosis outcome
(19). Dragt et al. showed that younger age of onset of cannabis
use is associated with earlier symptoms of anxiety, social with-
drawal, derealization, memory impairment, and difficulties in
concentration, with effects being more pronounced in patients
with heavier cannabis use (250). Another recent study found that
early onset cannabis use was only associated with earlier onset
of psychosis when cannabis use began by age 14 (251). A large
meta-analysis of 83 studies found that the age of onset of psy-
chosis in cannabis users was 2.7 years younger than in non-users
(252). Animal studies have shown that exposure to cannabinoids
in adolescence has more deleterious effects than exposure in
adulthood (253–257).
It is being increasingly recognized that adolescence may be a
particularly critical period of increased vulnerability to the effects
of cannabis. Additionally, factors such as schizotypy, other trait
measures of liability to psychosis, and childhood abuse may mod-
erate the risk of schizophrenia with prolonged and persistent
cannabis use. As discussed above, the 26-year longitudinal study
of the Dunedin cohort showed that earlier cannabis use is asso-
ciated with a greater risk of psychotic disorder. However, when
adjusted for psychotic symptoms at age 11, the association between
cannabis use and subsequent psychotic disorder was no longer sig-
nificant but remained elevated (OR= 3.1) (19). The small sample
size may limit the interpretation of these results.
These studies suggest a “window of vulnerability” hypothesis: a
critical period during early adolescence where the brain is particu-
larly susceptible to the psychosis-inducing effects of cannabis (19,
250, 251, 253–258). One possible explanation for the “window of
vulnerability” theory is that cannabis may affect the brain during
a critical period of development and maturation. Brain develop-
ment and maturation processes – including neuronal migration
and differentiation, synaptogenesis, axon formation, and den-
dritic proliferation, myelination, pruning, apoptosis, and activity-
dependent changes – begin in utero but continue into the early
20s or even later (259–264). Cannabis may disrupt one or more of
these processes.
A retrospective study of 997 subjects by Stefanis and colleagues
showed that, after adjusting for family history, there was a consis-
tent relationship between the age of cannabis initiation and FEP,
with an average time of 7–8 years (265). This finding does not sup-
port the“window of vulnerability”hypothesis, but rather indicates
that the brain (at least in years 12–19) is continually sensitive to
cannabis.
The association between age of onset of cannabis use and
worse outcomes could simply reflect that earlier use is more likely
to become longstanding, thus increasing the overall exposure to
cannabis. An alternate explanation for the association between age
of exposure to cannabis and psychosis is that those prone to early
psychosis may “self-medicate” with cannabis to relieve symptoms
(22, 266). However, this has not been supported by recent literature
(28, 250, 251, 267). These studies are limited in that they have relied
on measuring only positive psychotic symptoms as an indication
of psychosis onset, although it is known that negative symptoms
and cognitive deficits predate the onset of positive symptoms (268)
and even predict conversion to psychosis in high-risk individuals
(269). The interpretation of the data is also limited by the fact
that cannabis use at an early age may be part of a broader pattern
of externalizing behavior in response to difficult family circum-
stances (270, 271). Children and adolescents who begin cannabis
use at an earlier age may represent a distinct sub-population that
differs in ways that have not been accounted for (such as history
of abuse or family socio-economic level) in the aforementioned
studies.
FAMILY HISTORY
Early studies have indicated that a positive family history of
schizophrenia may increase risk for cannabis-induced psychotic
disorders. One such study found that among patients admitted
for acute psychosis, those who tested positive for cannabinoids in
urine toxicology screens were 10 times more likely (7.1 vs. 0.7%) to
have a positive family history for schizophrenia than patients with-
out a positive urine toxicology screen (272). This finding impli-
cated a familial predisposition to persistent psychotic disorders
precipitated by cannabis use. Thus, in a genetically predisposed
sub-population, cannabis confers a marked risk for psychosis.
Most studies since have confirmed an association between a family
history of psychotic disorder and an increased risk of cannabis-
induced psychosis, though the association is more modest than
the original study. Bersani et al. found that among schizophrenia
patients, 24% of cannabis users had a positive family history of
psychotic disorder vs. 10% (217). The largest study to investigate
this association (n= 2,276,309) found a 2.5-fold increased risk
of developing cannabis-induced psychosis in children of mothers
with schizophrenia but no increased risk of conversion to schizo-
phrenia (273). Further studies that have followed patients over
time have shown that among patients who are admitted with
an initial diagnosis of cannabis-induced psychosis, almost 50%
convert to schizophrenia or some other psychotic disorder (181,
188). Boydell et al., found, in a retrospective study of 757 first-
episode schizophrenia patients (24% who used cannabis in the
year prior to presentation), that among patients with schizophre-
nia, cannabis users did not differ significantly from those not using
cannabis in terms of a positive family history of schizophrenia
(15 vs. 12%) (274). More recently, investigators from the Genetic
Risk and Outcome of Psychosis (GROUP) collaboration studied
a large sample of patients with a psychotic disorder (n= 1120),
their siblings (n= 1057), and community controls (n= 590). In
this prospective, ongoing study, the investigators found that the
effect size of the relationship between current cannabis use and
both positive and negative schizotypy symptoms was significantly
greater in siblings of patients with a psychotic disorder when com-
pared to healthy,un-related control. Further, there was a significant
association between cannabis-using siblings and their psychotic
patient relatives (in terms of positive symptoms), whereas this
association did not emerge among non-exposed siblings and their
psychotic relatives. The authors proposed that the familial liability
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to psychosis is expressed partially in terms of psychotomimetic
experiences with cannabis (GROUP).
HISTORY OF CHILDHOOD ABUSE
More recently, the interactive effects of childhood maltreatment
and cannabis abuse have been examined. In a cross-sectional study,
Houston and colleagues found an odds ratio of 11.96 (95% CI
2.10–68.22) for having experienced psychosis among children with
a history of abuse who used cannabis prior to age 16 (275). Another
cross-sectional study by Harley et al. found a significant interactive
effect of childhood trauma and cannabis use in moderating the risk
of psychotic symptoms; the odds ratio of experiencing psychosis in
adolescents with a history of exposure to trauma and cannabis was
20.9 (95% CI 2.3–173.5) (276). A longitudinal study has similarly
shown a significant interaction between cannabis use and child-
hood maltreatment in the development of psychotic symptoms
(277). Notably, there was no evidence in this study that base-
line history of childhood abuse affected subsequent cannabis use.
These findings, however, were not replicated in the EDSP dataset
(278). It is important to interpret the above findings with caution.
Some investigators (279) have shown a link between childhood
abuse and subsequent cannabis use; others demonstrate a link
between abuse and subsequent psychosis (280). Future studies,
which examine the interaction between genetic liability, trait mea-
sures of psychosis liability, cannabis use, and other environmental
factors may provide greater insights into the complex mechanisms
that cause psychosis.
GENETIC FACTORS
Genetic factors may confer vulnerability to psychosis outcomes
following exposure to cannabis, i.e., a gene-environment inter-
action. In specific, Catechol-O-methyltransferase (COMT) and
AKT1, have been implicated in conferring such vulnerability (see
Table 1). Preliminary evidence suggests that other genes might
also moderate the cannabis–psychosis interaction.
Catechol-O-methyltransferase
In one of the first studies that drew attention to gene× environment
interactions, Caspi et al. reported that the COMT gene moderated
the risk of psychotic disorder with adolescent cannabis exposure.
The enzyme COMT plays a critical role in the breakdown of
dopamine in the PFC (286), in contrast to the striatum where
DA is cleared by a transporter. The COMT gene has a common
polymorphism in humans, which results in 40% higher enzy-
matic activity and thus more rapid degradation of dopamine when
Valine (107) is substituted for Methionine (Met) at the 158/108
locus. Val/Val homozygotes have the lowest levels of dopamine;
Met/Met homozygotes have the highest levels; and heterozygotes
have intermediate levels. Lower cortical dopamine levels in indi-
viduals homozygous for theVal(158) polymorphism are associated
with, among other things, poorer cognitive performance, and
inefficient precortical functioning (287).
In a longitudinal prospective study (Dunedin cohort) of 803
individuals followed over 25 years, Caspi et al. showed that the
risk of developing of psychotic disorder in association with
cannabis exposure increased by 10-fold in those patients with
the Val/Val allele (200). There were subsequent attempts to
validate these findings with experimental evidence: a double-
blind, placebo-controlled cross-over study showed that individuals
with the Val polymorphism of the COMT gene have a higher
chance of developing acute psychosis in response to THC expo-
sure (133). These findings have been confirmed in a similar
experiment (288).
Recent studies have failed to confirm the findings of the original
2005 study from Caspi and colleagues. A case-only analysis of 1438
individuals found no interaction between COMT polymorphism
and cannabis use with regard to schizophrenia (281). Further, a
2-year longitudinal study of 2630 genotyped patients showed no
interaction between COMT and cumulative cannabis use on the
development of psychosis (282). A more recent case–control study
also showed no COMT-mediated increased cannabis risk in the
development of psychosis (284). Kantrowitz et al. were unable to
find an interaction between COMT polymorphisms and cannabis-
induced psychotic disorder in a population of 92 individuals with
psychotic disorder, though this study was under-powered. Sub-
analyses based on race (African American and Caucasian) did not
yield significant findings (289). In contrast to the original Caspi
et al. study (200), a case-only study from Spain (155 out of 748 total
schizophrenia subjects who used cannabis) actually found an asso-
ciation between the low-activity Met allele of COMT and cannabis
use in psychotic disorder (283). Estrada et al. (290) showed a dose-
effect of COMT polymorphism on the age of onset of psychosis
among cannabis users: individuals who were homozygous for the
Val allele of COMT had the earliest age of onset of psychotic disor-
ders at 15.4 years; homozygotes for the Met allele had the latest age
of onset at 18.8 years; heterozygotes with intermediate enzymatic
activity, had an age of onset of 17.1 years. Notwithstanding, there
was no overall greater risk for psychotic disorder found among any
of the polymorphism groups. A similar trend regarding the inter-
action of COMT polymorphism and cannabis use in association
with the age of onset of psychosis has been shown, though not all
results achieved statistical significance (291).
Other studies have examined the interactive effects of COMT
polymorphisms and other environmental factors. A cross-
sectional analysis of 918 individuals in Europe found a significant
three-way interaction between the COMT Val allele, cannabis
use, and childhood abuse in moderating psychosis. Individuals
homozygous for the Val polymorphism were more likely to expe-
rience psychosis in association with cannabis use in the context
of a history of childhood abuse than individuals homozygous or
heterozygous for the Met allele. A replicative sample as part of the
same study showed the same trend but did not achieve statisti-
cal significance (292). Confirming these findings, Alemany et al.
found that the three-way interaction of COMT polymorphism
(Val allele), cannabis use, and a positive history of child abuse sig-
nificantly increased the risk of both positive and negative psychotic
symptoms (293).
AKT1
AKT1 is another gene thought to play a role in moderating the asso-
ciation between cannabis and psychotic disorders. The enzyme
AKT1 functions to inactivate glycogen synthase kinase (GSK-
3) by phosphorylation (294). The interaction between AKT1
and GSK-3 has been implicated to play a role in a number of
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Table 1 | Gene× cannabis interactions in moderating risk of psychosis.
Gene/locus Study Study design Sample size Follow up Outcome – odds ratio (OR)/relative risk (RR)
COMT /rs4680 Caspi et al.
(200)
Longitudinal,
prospective (Dunedin
cohort)
803 26 years OR 10.9 (95% CI 2.2–54.1) of developing psychotic
disorder in Val/Val genotype
OR 2.5 (95% CI 0.78–8.2) of developing psychotic
disorder in Val/Met allele
OR 1.1 (95% CI 0.21–5.4) of developing psychotic
disorder in Met/Met allele
COMT /rs4680 Zammit
et al. (281)
Case-only,
cross-sectional analysis
493 NA OR 0.98 (95% CI 0.76–1.27) for history of cannabis
use in schizophrenia subjects with Val/Val allele
COMT /rs4680 Zammit
et al. (282)
Longitudinal (Avon
cohort)
2630 2 years OR 1.0 (95% CI 0.73–1.36) of cannabis×COMT
interaction
OR 1.56 (95% CI 1.05–2.31) of psychosis in
cannabis users with Met/Met genotype
OR 1.47(95% CI 0.85–2.26) of psychosis in
cannabis users with Val/Val genotype
OR 1.68 (95% CI 1.23–2.28) of psychosis in
cannabis users with Met/Val genotype
COMT /rs4680 Costas
et al. (283)
Case-only,
cross-sectional analysis
748 NA OR 2.07 (95% CI 1.27–3.26) of history of cannabis
use in schizophrenia pts w/Met/Met genotype vs.
Val/Val genotype
AKT1/rs2494732 van Winkel
(284)
Cross-sectional analysis 801 Subjects
with psychosis
NA RR 1.90 (p<0.01) of C/C genotype in daily
cannabis users – case-only analysis
740 Unaffected
siblings
OR 1.96 (95% CI 1.09–3.53) of being diagnosed
with psychotic disorder in C/C allele
subjects – case–sibling analysis
419 Controls OR 2.08 (95% CI 0.92–4.67) of being diagnosed
with psychotic disorder in C/C allele
subjects – case–control analysis
AKT1/rs2494732 Di Forti
et al. (285)
Case–control,
cross-sectional analysis
489 Subjects NA OR 7.23 (95% CI 1.37–38.12) of psychotic disorder
in C/C genotype subjects with daily cannabis use
vs. T/T genotype
278 Controls OR 2.18 (95% CI 1.12–4.31) of psychotic disorder in
C/C genotype subjects with history of cannabis use
OR, odds ratio; RR, relative risk; CI, confidence interval.
important cellular processes, such as cell proliferation, apopto-
sis, and transcription (295). In vitro studies have shown that
cannabinoids are capable of stimulating the AKT1 pathway via
CB1 and CB2 receptors (296) and in vivo studies in mice have
also confirmed this (297). Further, the gene product has been
implicated in schizophrenia: postmortem studies have shown
decreased AKT1 levels in lymphoblasts in the PFC of patients with
schizophrenia (298, 299).
In a sample comprised of 801 patients with psychosis, 740 of
their unaffected siblings, and 419 controls, van Winkel showed
that cannabis users with the C/C genotype of a specific polymor-
phism (rs2494732) of theAKT1 gene had a twofold increase in risk
of being diagnosed with psychotic disorder (284). Additionally,
among psychotic patients, those homozygous for the C allele were
twice as likely to have a history of daily cannabis use compared
with T/T genotypes. The significance of the AKT1× cannabis
interaction held among case-only (p= 0.007) and case–sibling
(p= 0.04) sub-analyses; in the case–control sub-analysis, the
AKT1× cannabis interaction approached statistical significance
(p= 0.057). A more recent study has replicated these findings and
found an even stronger interaction. Di Forti and colleagues studied
489 patients with FEP and 278 control subjects in a case–control
design; among daily cannabis users, those who carried the C/C
allele had, on average, a sevenfold increase in the risk of psychosis
compared to T/T carriers (285). Notably, carriers of this genotype
(C/C at SNP rs2494732) also have been shown to have increased
cognitive side effects from cannabis use as evidenced by lower
scores on tests of sustained attention (300). Preliminary exper-
imental evidence has also implicated a different polymorphism
of the AKT1 gene (the GG genotype of the SNP rs1130233) as a
moderator of sensitivity to the acute psychosis-inducing effect of
THC (301).
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Other genes
Another gene implicated in moderating the effects of cannabis
on the development of psychosis is DAT1, which codes for the
dopamine transporter, which is critical in removing DA from the
synapse in striatal regions. A polymorphism involving a variable
number of tandem repeats (VNTR) has been described in the 3′
untranslated region of the DAT1 gene (SLC6A3). One of the com-
mon alleles of this polymorphism (the nine-repeat allele) is associ-
ated with lower enzymatic activity and thus higher dopamine levels
in the striatum. DAT1 has previously been associated with schizo-
phrenia (independent of cannabis use) in gene association studies
(302). Bhattacharyya et al., reported that individuals with the
nine-repeat allele showed increased sensitivity to THC-induced
psychotomimetic effects in a small laboratory based study (n= 35)
(301). There was also a trend toward greater THC-induced psy-
chotomimetic effects in individuals with the G/G genotype of the
rs1130233 polymorphism of the AKT1 gene in the same sample.
Furthermore, there was a synergistic interaction between these
DAT and AKT1 genotypes on the psychotomimetic effects of
THC. In addition to studying behavioral effects of THC, this study
showed interactive effects of DAT1 genotype,AKT1 genotype, and
THC on striatal and midbrain activation during encoding and
recall of verbal information, respectively. Individuals with the GG
allele at AKT1 and carriers of the nine-repeat allele of DAT1 also
showed increased activation in the striatum in response to THC
in comparison to the rest.
Neuregulin 1 (NRG1), a leading schizophrenia susceptibility
gene, is relevant to several schizophrenia-related neurodevelop-
mental processes (303, 304). Heterozygous deletion of NRG1
results in increased sensitivity of mice to schizophrenia-like symp-
toms induced by THC especially under stressful conditions (305).
These mice also showed greater increases in prepulse inhibition
(PPI), a marker for sensorimotor gating known to be impaired in
schizophrenia, following THC administration (305). However, to
our knowledge, this work has not yet been extended to humans.
Decoster et al. reported significant interactions between brain-
derived neurotrophic factor (BDNF) genotype, cannabis exposure,
and gender in a cohort of schizophrenia patients: in female patients
only, cannabis use was associated with earlier age of onset of psy-
chosis in BDNF Met-carriers relative to Val/Val-genotypes (306).
Additionally, cannabis use may interact with specific genotypes of
the cannabinoid receptor 1 (CNR1) gene to moderate cognitive
impairment in schizophrenia patients (307), but thus far no sig-
nificant interaction between CNR1 polymorphisms and cannabis
exposure on the risk for the development of psychotic disorders
has been reported (281).
CANNABIS, SCHIZOPHRENIA, AND CAUSALITY
The association between cannabis and psychosis fulfills many but
not all of the standard criteria for causality (308), namely temporal
relationship, biological gradient, biological plausibility, coherence,
consistency, and experimental evidence.
TEMPORAL RELATIONSHIP
As discussed above, evidence from experimental studies shows
a clear temporal relationship between exposure to cannabinoids
and symptoms of psychosis. Despite a number of limitations (dis-
cussed previously), several epidemiological studies have concluded
that cannabis use generally precedes the development of psy-
chotic disorder. In one of the earliest such studies, Allebeck and
colleagues found that cannabis use preceded the onset of schizo-
phrenia by at least 1 year in 69% of cases; in only 11% of cases did
cannabis succeed psychosis (309). In a prospective cohort study,
Linszen et al. found that in all but 1 patient from a sample of
24 cannabis-abusing patients, cannabis abuse preceded FEP by at
least 1 year (310).
Studies from recent years suggest that in the majority of cases,
cannabis use precedes the onset of psychosis, rather than vice versa.
In a study of 28 FEP patients, cannabis use preceded psychosis in
all patients (267). Another study of 45 psychotic disorder patients
with a history of cannabis use showed that the onset of cannabis
use preceded hallucinations in 74% of cases and preceded persecu-
tory ideas in 90% of cases by at least on year (250). Schimmelmann
and associates (251) reported that in 88% of cases (n= 201 FEP
patients with cannabis use), drug exposure preceded psychotic
symptoms by a mean of 5 years.
As discussed above, numerous additional studies have shown
that cannabis users have a younger age of onset of psychotic disor-
ders compared to non-users (197, 250, 258, 309–312). A recent
meta-analysis of over 22,000 subjects found the onset of psy-
chosis was 2.7 years younger in cannabis users than in non-users
(252). These studies lend further evidence to the finding that
cannabis usually precedes the onset of psychotic symptoms and
argue against the “self-medication” hypothesis.
The findings from epidemiological studies regarding the tem-
poral relationship between cannabis and psychosis must be qual-
ified. Epidemiological studies have traditionally examined the
relationship of cannabis use and psychosis as defined by posi-
tive psychotic symptoms. It is unclear whether the same temporal
relationship holds for cognitive deficits or negative symptoms of
psychosis, which usually predate the onset of positive psychotic
symptoms. Furthermore, the data fails to explain why patients with
schizophrenia continue to abuse cannabis. Cannabis continues to
be among the most common illicit drug used by patients with
schizophrenia. In the Australian Study of High Impact Psychoses
(313), 49% of patients with schizophrenia reported exposure to
cannabis in the past year (314). In a study among patients with
schizophrenia using experience-sampling, Henquet et al. (315)
found that compared to healthy control, patient with schizophre-
nia reported a reduction in negative affect after cannabis use, while
the increase in positive affect that they experienced was compa-
rable to controls. Schizophrenia is a disease of gradual onset and
diagnosis usually occurs only when a patient’s symptoms are severe
enough to cause disruptions in psychosocial functioning. If, as has
been hypothesized, schizophrenia is a neurodevelopmental disor-
der in which neurobiological changes occur years before the onset
of symptoms, then these studies have been unable to examine the
true temporal relationship between psychosis and cannabis. On
the other hand, if cannabis induces schizophrenia in individu-
als who are genetically vulnerable (see discussion below) and thus
exhibit“prodromal”symptoms at baseline, then the exact temporal
nature of this relationship is extremely relevant.
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BIOLOGICAL GRADIENT
There are a number of limitations to assessing the dose of exposure
of cannabis and its effect on psychotic outcome. Whereas ciga-
rettes and alcoholic beverages have standardized and well-known
quantities of nicotine and alcohol, the THC content of cannabis
varies considerably. Further, when people smoke cannabis, they
may smoke the same joint over several sessions or share a joint
with others. Therefore, the number of times a person has smoked
is a crude proxy of the “dose” of cannabis exposure. Finally, as
discussed above, CBD is thought to have antipsychotic effects in
opposition to the pro-psychotic effects of THC. The variable con-
tent of CBD in marijuana further complicates the interpretation
of studies investigating a dose–response effect.
Despite these limitations, a consistent dose–response effect has
been shown in numerous studies. One of the earliest studies show-
ing a biological gradient in the association between cannabis use
and psychotic symptoms was done by Andreasson and colleagues.
Using the Swedish military conscript (n> 45,000) followed over
a 15-year period (described in detail previously), the investigators
found that individuals with heavier cannabis use (>50 occasions of
consumption) had a greater chance of developing schizophrenia
(relative risk 6.0); intermediate users (11–50 occasions of con-
sumption) had a relative risk of 3.0 for developing schizophrenia.
After adjusting for various potential confounders (school adjust-
ment, socio-economic status, solvent abuse, psychiatric diagnosis
or medications at baseline,and others,but not including childhood
abuse/trauma), the relative risk remained elevated and statisti-
cally significant (197). A follow up of this same cohort at 27 years
found that this dose–response relationship between cannabis con-
sumption and risk of developing schizophrenia persisted over time
(198). Other studies previously described, including the NEMESIS
(20) and the ESDP cohorts (24) have also suggested a biologi-
cal gradient between exposure load and psychotic outcome. More
recent evidence also supports this dose–response effect in a sample
of individuals with sub-clinical psychotic symptoms; this sample
showed that among heaviest users (>5 per day) the relative risk,
after adjusting for confounders (“sex, age, social exclusion, alcohol,
cannabis use before age 17, and heavy non-cannabis drug use”), of
experiencing auditory hallucinations was 5.4 and relative risk for
first-rank symptoms was 11.6 (316).
SPECIFICITY
The specificity of the association between cannabis and psychotic
disorders is low. In a prospective study of 3-year follow up, of all
patients who developed psychosis (assessed by BPRS), only 21%
had any use of cannabis at baseline. Furthermore, of those who
used cannabis at baseline, only 8 in 312 subjects (2.6%) devel-
oped psychosis (20). Similar data was reported from the Swedish
military conscript cohort (197). While the association between
cannabis and schizophrenia is not specific, it is stronger and more
consistent than the association between cannabis and anxiety or
depressive disorders. Odds ratios for the development of anxiety
or depressive disorders with exposure to cannabis typically range
from 0.7 to 1.5 with many studies yielding statistically insignifi-
cant results; in contrast, a meta-analysis of multiple longitudinal
prospective studies found a statistically significant, adjusted odds
ratio of 2.09 (95% CI 1.54–2.84) for psychosis outcome among
heaviest cannabis users with all but one of the six high-quality, lon-
gitudinal studies showing a statistically significant outcome. These
longitudinal studies controlled for about 60 different potential
confounders, including personality traits, socio-economic mark-
ers, other substance use, and other mental health problems (25).
In a longitudinal study of over 18,000 patients hospitalized for
substance-induced psychosis, the 8-year cumulative risk of con-
version to schizophrenia was 46% when the offending substance
was cannabis. In contrast, the conversion rate to schizophrenia
over the same period of time for alcohol-induced psychosis was
5%. Notably, the risk for the development of schizophrenia when
the diagnosis was amphetamine-induced psychosis was 30% (188).
CONSISTENCY
While not all epidemiological studies have detected an association
between cannabis use and psychosis, most longitudinal studies
(described in detail previously) show a statistically significant
increased risk of psychosis outcome in those who use cannabis
heavily. Among each study’s heaviest users, the following longi-
tudinal studies have demonstrated a significantly increased risk
of any psychosis outcome: the Swedish military conscript cohort
(heaviest users being those who had used marijuana >50 times)
(197–199), the NEMESIS cohort (weekly users) (20), EDSP cohort
(daily users) (24), Epidemiological Catchment Area study (daily
users) (317), Dunedin cohort (19, 200), and the CDHS cohort
(daily users) (23). The National Psychiatric Morbidity Survey
found an increased odds ratio (adjusted for alcohol consump-
tion, gender, IQ score, marital status, and others) that was not
statistically significant (even in their heaviest using subjects, those
with cannabis dependence) (318). Among these same studies, an
analysis of those who had ever used marijuana (even if just once),
the Epidemiological Catchment Area study, EDSP study, and the
NEMESIS cohort showed increased risk of any psychosis outcome
but this risk was not statistically significant.
BIOLOGICAL PLAUSIBILITY
The precise pathophysiology of psychosis or psychotic disorders
remains unclear; therefore, a biologically plausible mechanism
whereby exposure to cannabis can increase the risk for psychosis
or a psychotic disorder is yet to be established. THC, the princi-
pal active component of cannabis, is a partial agonist at CB1Rs
where it has modest affinity (K i= 35–80 nmol) and low intrinsic
activity (319). CB1Rs are G-protein-mediated receptors that are
distributed with high density in the cerebral cortex (particularly
frontal regions), basal ganglia, hippocampus, anterior cingulate
cortex, and cerebellum; these brain regions have been implicated
in the putative neural circuitry of psychosis. The primary effect
of cannabinoids is the modulation of neurotransmitter release via
activation of presynaptic CB1Rs. Thus cannabinoids, by activating
CB1Rs, can modulate the release of a number of neurotransmitters
already implicated in psychosis, including dopamine, glutamate
or GABA.
The dopamine hypothesis, which postulates that positive symp-
toms of psychosis may be attributed to disturbed and hyperactive
dopaminergic activity, remains one of the more enduring and
dominant hypotheses of schizophrenia (320). CB1R-mediated
increases in mesolimbic dopaminergic activity may explain the
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positive psychotic symptoms induced by THC. Converging pre-
clinical evidence suggests interactions between cannabinoid (CB1)
and dopamine (DA) systems [reviewed in Ref. (321, 322)]. CB1 and
D2 receptors are co-expressed in several brain regions (323) and
there is signal transduction convergence in these regions (324).
Cannabinoids have been shown to induce firing of dopaminer-
gic mesolimbic neurons and induce DA release in the striatum
in animals (100, 321, 325–329). Cannabinoids regulate DA fir-
ing via a CB1-GABAergic-mediated disinhibition of DA neuronal
activation. However, the results of in vivo imaging studies of THC-
induced striatal dopamine release in humans have been mixed (96,
330–332). The effect of cannabinoids on striatal dopamine release
may be differentially affected by biological vulnerability for psy-
chosis. While chronic cannabis use was found to be associated
with decreased striatal dopamine synthesis in healthy individu-
als (332), THC was found to increase striatal dopamine release in
first-degree relatives of individuals with psychotic disorder (333).
The effects of cannabinoids on dopaminergic systems in the
PFC might account for some of their acute cognitive deficits. It is
well-know that either too much or too little dopaminergic activity
in the PFC is associated with impairments in PFC-related cogni-
tive functions leading to an inverted “U” (bell shaped) relationship
between dopamine levels and working memory efficiency (334,
335). Systemic administration of cannabinoids has been reported
to increase prefrontal cortical DA release or turnover in sev-
eral studies (100, 336–339). This may explain how cannabinoids
produce acute impairments in PFC-related cognitive functions
including working memory and attention.
Cannabinoids might induce psychosis and cognitive impair-
ments via actions on GABAergic systems. Higher order cognitive
processes, including working memory, are associated with θ (4–
7 Hz) and γ (30–80 Hz) oscillations in the PFC. Deficits in working
memory are a hallmark of schizophrenia and are associated with
reduced cortical θ and γ band power. Cortical θ and γ oscillations
are dependent on inhibition of pyramidal neurons. This inhibition
is driven by specific cholecystokinin (CCKb cells) and parvalbu-
min (PVb cells) containing GABAergic interneurons. In several
brain regions, CB1Rs are present on the terminals of axons in
cholecystokinin (CCK)-containing GABA interneurons that tar-
get the perisomatic regions of pyramidal cells (340). Activation of
CB1R reduces GABA release, which in turn releases the inhibition
effects on pyramidal cells. While admittedly speculative, the disin-
hibition of pyramidal cells may lead to cortical oscillation deficits
and working memory impairments.
While the acute effects of cannabinoids on DA, GABA, and glu-
tamate neurotransmission may explain some of the acute positive,
negative, and cognitive symptoms of cannabinoids, the mecha-
nism by which exposure to cannabinoids might cause schizophre-
nia has not yet been established. If schizophrenia is a neurode-
velopmental illness (341, 342), then the observation that early
cannabis exposure is associated with a greater risk for the devel-
opment of schizophrenia may offer some clues to the underlying
biological mechanisms. Consistent with the human epidemiolog-
ical data, animal studies suggest that early (adolescent) but not
later (adult) exposure to cannabinoids is associated with persis-
tent impaired social behaviors, including psychotic-like behaviors,
cognitive, and sensorimotor gating deficits in adults (253–257).
Adolescence and young adulthood are critical phases for cere-
bral development. Brain development continues into young adult-
hood (up to 25 years) (343) and therefore, any factors that interfere
with brain development during this time may have far reaching
consequences. During this period of neuronal plasticity, there is
sprouting and pruning of synapses, myelinization, changes in neu-
rotransmitter concentrations and their receptor levels in brain
areas necessary for behavioral and cognitive functions (344).
The endocannabinoid system plays an important role in several
processes important in neurodevelopment including neurogene-
sis, neural specification, neural maturation, neuronal migration,
axonal elongation, glia formation, and positioning of inhibitory
GABAergic interneurons and excitatory glutamatergic neurons
(259–262, 345–349). Perturbation of the endocannabinoid sys-
tem in the rapidly changing brain, as is the case in adolescence, by
excessive or non-physiological stimulation, as may be the case with
exposure to exogenous cannabinoids, may have far reaching con-
sequences. This would be especially so in the presence of already
altered neurodevelopmental processes. Therefore, by disrupting
the endocannabinoid system and interfering with neurodevelop-
mental processes, exogenous cannabinoids may provide a biolog-
ically plausible mechanism by which exposure to cannabinoids
during adolescence may increase the risk for the development of
schizophrenia.
STRENGTH OF ASSOCIATION
In the general population, the strength of association between any
cannabis exposure and the development of psychosis is modest.
A systematic review of 35 longitudinal studies found the relative
risk of developing schizophrenia after any cannabis exposure to
be 1.4 after adjusting for about 60 potentially confounding vari-
ables, including personality traits, socio-economic markers, other
substance use, and other mental health problems (25). However,
as discussed above, in heavy users (as well as those who begin
use at earlier ages), the risk can be much greater. A follow up of
the original Swedish military conscript after 35 years yielded an
adjusted relative risk of 3.7 for the development of a psychotic
disorder (199).
Indirect but compelling evidence is seen in conversion of
cannabis-induced psychosis to schizophrenia. Longitudinal stud-
ies have found that the risk of developing schizophrenia is nearly
50% in patients admitted for cannabis-induced psychosis (181,
188). Such findings suggest that genetic (or other predisposing)
susceptibility to cannabis-induced psychosis may explain why the
cannabis–schizophrenia association does not fulfill all causality
criteria. That is, in a sub-population of individuals with a his-
tory of childhood abuse and genetic vulnerability, the association
between cannabis and schizophrenia may be significantly stronger
and more specific than in the general population. Individuals
with neurobiological vulnerabilities who develop acute psychosis,
which persists for a limited period after cannabis intoxication may
be those who, with prolonged exposure, are more likely to develop
permanent psychotic disorders.
EXPERIMENTAL EVIDENCE
As noted above, direct experimental evidence for acute and tran-
sient psychosis caused by cannabis intoxication is compelling (89,
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95). In some individuals, this effect persists after the acute intoxica-
tion period has ended. In randomized, placebo-controlled, exper-
imental settings, acute psychosis in response to THC intoxication
is quite common and reproducible (89, 95, 350). Positive (para-
noia, grandiose delusions, fragmented thinking, and perceptual
alterations), negative (blunted affect, emotional withdrawal, and
psychomotor slowing), and cognitive symptoms (impairments of
abstraction, attention, executive function, and memory) have been
well-documented. Thus, the main symptom clusters of schizo-
phrenia are seen acutely with THC intoxication. Occasionally,
immediate psychosis precipitated by cannabis persists beyond the
period of intoxication and may require intervention, though most
of these data come from case reports and small series rather than
experimental evidence.
Unlike studying acute effects, an experimental approach to
characterize the effects of chronic, heavy, and early cannabis expo-
sure is neither ethical nor feasible. An alternative approach is to
compare a group with chronic, heavy early cannabis use to con-
trols. Such samples do exist and have been discussed in detail
previously.
COHERENCE
There is substantial coherence between the laboratory study find-
ings and epidemiological findings regarding the acute effects
of cannabinoids. Cannabinoids induce a range of psychosis-like
effects in laboratory studies and epidemiological studies are replete
with reports of psychosis following the consumption of cannabi-
noids. Similarly, cannabinoids have been shown to exacerbate
symptoms in individuals with a psychotic disorder and epidemi-
ological studies have shown that cannabis use by schizophrenia
patients is associated with a negative impact on the expression and
course of the illness. However, as an experimental approach to
characterize the effects of chronic, heavy, and early cannabis expo-
sure is neither ethical nor feasible, it is impossible to determine
coherence between laboratory and epidemiological studies with
regard to the consequences of chronic, early, and heavy cannabis
use and psychosis.
PARALLELS
Several parallels can be drawn between the cannabis–psychosis
association and other associations in medicine that have been
accepted to be causal in nature. For instance, excess salt consump-
tion has been shown to be a well-established cause of hypertension
(351), yet not all people who consume more than 2 g of salt daily
have hypertension. Similarly, most people who smoke cigarettes
do not develop lung cancer; further, there are types of lung cancer
(i.e., adenocarcinoma), which develop in the absence of smok-
ing. Yet smoking is understood to be the single most important
modifiable causal component in the development of lung cancer.
It is unlikely that schizophrenia is a homogenous disorder with
a single pathophysiology; instead, it is more likely a syndrome with
distinct neurobiological etiologies. Similarly, the term “lung can-
cer” comprises several different histological types, including ade-
nocarcinoma, squamous cell carcinoma, and small-cell carcinoma.
The risk that smoking confers in the development of cancer varies
considerably as the sub-type of cancer becomes more specific. For
instance, the risk of developing various types of cancer (including
liver, kidney, cervical, myeloid leukemia, gastric, nasopharyngeal,
nasal, or esophageal adenocarcinoma) among current smokers
may be relatively low, with estimates of the relative risk being
~1.5–2.0 (352). In a large meta-analysis, the relative risk of devel-
oping any lung cancer among current smokers is much higher at
8.43 (95% CI 7.63–9.31); the relative risk of developing squamous
cell carcinoma of the lung is even higher, recently cited at 16.43
(95% CI 12.66–21.32) (353). Viewed from another perspective
of the analogy, it is estimated that tobacco smoke is responsible
for ~21% of all types of cancer-related deaths worldwide (354)
and 87% of all deaths related to lung cancer (2013). By compar-
ison, it is estimated that 8–14% cases of schizophrenia may be
due to cannabis use (25, 207). Therefore, the magnitude of the
risk for schizophrenia conferred by cannabis exposure is signifi-
cantly lower than the risk of lung cancer conferred by smoking. It is
unlikely that there is any single cause of an illness as heterogeneous
as schizophrenia. As research progresses and our understanding of
the biological causes of mental illness advances, cannabis-induced
psychotic disorder may emerge as a distinct sub-type among the
different disorders that constitute what we now classify broadly as
schizophrenia.
In summary, the relationship between cannabinoids and psy-
chosis fulfills many but not all of the traditional criteria for
causality. Given the evidence presented above, it is likely that
cannabis is an important component cause in the development of
psychotic disorders (16, 205). This causal role is likely magnified
when cannabis exposure occurs at an earlier age, in greater quanti-
ties, and over a longer time-course. Further, as discussed elsewhere
in this review, specific populations (i.e., those with a genetic vul-
nerability or a history of childhood abuse) may be particularly
susceptible to the causal effects of cannabis. Notably, although
meta-analytical studies suggest that cannabis might account for
between 8 and 14% of schizophrenia cases (25, 207), the fourfold
increase in the rates of cannabis use over the last four decades
(198, 355) has not resulted in a commensurate 40–70% increase
in prevalence of schizophrenia. Some studies suggest that the rates
of schizophrenia may be decreasing (356), while others suggest the
contrary (357, 358). The discrepancy between the recent changes
in the rates of cannabis consumption and relative stability of schiz-
ophrenia rates are difficult to explain in the context of the findings
reviewed above; one possible explanation is that schizophrenia
rates are lagging behind increased rates of cannabis consumption.
Again, it is important to note that schizophrenia is likely a very het-
erogeneous illness, comprised of multiple sub-types. It is unlikely
that there is a single causative factor. As proposed by Rounsaville,
it is possible that a cannabis-induced psychotic disorder comprises
one of the distinct sub-types of the schizophrenia-spectrum (191).
SUMMARY AND CONCLUSION
In summary,acute exposure to both natural and synthetic cannabi-
noids can produce a full range of transient symptoms, cognitive
deficits, and psychophysiological abnormalities that bear a strik-
ing resemblance to some of the features of schizophrenia. Also
clear is that, in individuals with an established psychotic disor-
der, cannabinoids can exacerbate symptoms, trigger relapse, and
have negative consequences on the course of the illness. Finally,
exposure to cannabinoids in adolescence confers a higher risk for
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psychosis outcomes in later life and the risk is dose-related. How-
ever, it should be remembered that the majority of individuals who
consume cannabis do not experience any kind of psychosis.
The findings from research reviewed above have profound
implications for public health. Aside from alcohol, cannabis is
currently the most prevalent drug used worldwide. In the United
States, the legal status of cannabis for medical and recreational
purposes is changing rapidly. Pertinent findings that are likely to
impact public health include high conversion rates from cannabis-
induced psychosis to schizophrenia; global and specific domains
of cognitive impairment resulting from cannabis use, which may
be irreversible; the effects of acute intoxication; the precipita-
tion of psychotic disorders in genetically vulnerable populations,
including individuals with a history of childhood abuse or family
history of psychotic disorders; and the increased risk of negative
effects of cannabis use in prolonged and early exposure. Additional
high-quality epidemiological studies are needed to further char-
acterize the extent to which cannabis causes these negative effects
or unmasks them in a vulnerable subset of the population.
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